What are Regeneron Pharmaceuticals's profit margins?

Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.

Where do Regeneron Pharmaceuticals's ratios come from?

Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Regeneron Pharmaceuticals REGN Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Operating margin	102.2%-10.8pp	105.1%-10.1pp	108.2%-9.7pp	111%-10.4pp	112.9%-13.7pp
Net margin	124.6%-4.1pp	126.8%+0.7pp	126.5%+1.3pp	128%+5.9pp	128.7%+4.7pp
EBITDA margin	116.9%-9.7pp	119.6%-9.0pp	122.4%-8.8pp	124.9%-9.5pp	126.6%-12.8pp
Free cash flow margin	112.8%+15.4pp	107.2%+0.9pp	104.6%-5.5pp	99.8%-20.6pp	97.3%-31.2pp
Returns
Return on equity	59.9%-5.7pp	61.4%-3.6pp	62.4%-2.8pp	64.4%-0.9pp	65.6%-2.4pp
Return on assets	46.6%-4.7pp	47.8%-2.9pp	48.8%-2.2pp	50.3%-0.6pp	51.3%-1.6pp
Return on invested capital	43%-9.6pp	45%-10.1pp	48%-9.6pp	50.7%-10.2pp	52.6%-12.2pp
Efficiency
Asset turnover	1.5×-0.1×	1.5×-0.1×	1.5×-0.1×	1.6×-0.1×	1.6×-0.1×
Liquidity
Current ratio	16.4×-4.0×	17.7×-3.0×	18.3×-3.4×	19.5×-2.0×	20.4×-1.2×
Quick ratio	13.4×-3.7×	14.5×-3.1×	15×-3.5×	16.2×-2.4×	17.1×-1.5×
Cash ratio	2.4×-0.2×	2.7×+0.2×	2.6×0.0×	2.6×-0.1×	2.6×-0.2×
Leverage
Debt-to-equity	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×	0.4×0.0×
Debt-to-assets	0.3×0.0×	0.3×0.0×	0.3×0.0×	0.3×0.0×	0.3×0.0×
Net debt / EBITDA	0.1×-0.2×	0.1×-0.4×	0.2×-0.2×	0.3×0.0×	0.3×0.0×
Interest coverage	349.8×+76.0×	354.4×+107×	345×+114×	320.5×+94.0×	273.8×+43.4×
Per Share
Book value per share	$1,144.05+12.6%	$1,116.56+13.2%	$1,083.77+12.9%	$1,047.36+13.0%	$1,016.10+13.7%
Valuation
Market capitalization	$278.79B-25.6%	$266.44B-34.9%	$263.6B-37.9%	$317.64B-20.2%	$374.55B+3.7%
Enterprise value	$279.25B-25.7%	$266.78B-35.1%	$264.54B-37.9%	$319.08B-20.2%	$376.08B+3.7%
Price / earnings	62.1×-21.6×	59.1×-36.2×	58.8×-42.4×	70.2×-28.5×	83.8×-6.5×
Price / sales	19.3×-7.8×	18.7×-11.3×	18.6×-13.1×	22.6×-7.5×	27×-0.7×
Price / book	9×-3.9×	8.8×-5.6×	8.8×-6.5×	10.8×-4.2×	12.9×-1.2×
EV / EBITDA	66.5×-19.0×	62.9×-30.8×	60.8×-36.3×	72.4×-18.0×	85.4×+4.9×
EV / sales	19.3×-7.8×	18.8×-11.4×	18.7×-13.1×	22.7×-7.5×	27.2×-0.7×
Free cash flow yield	24%+8.9pp	23.4%+8.9pp	23.1%+9.1pp	19%+2.8pp	15.1%-3.6pp
Earnings yield	26.6%+6.5pp	27.6%+10.4pp	27.7%+11.9pp	24.1%+7.8pp	20%+1.9pp
Dividend yield	1.7%+1.6pp	1.4%—	0.9%—	0.5%—	0.1%—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Regeneron Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Regeneron Pharmaceuticals's profit margins?: Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.
Where do Regeneron Pharmaceuticals's ratios come from?: Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.